EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Risk Assessment of Transgender People: Development of Rodent Models Mimicking Gender-Affirming Hormone Therapies and Identification of Sex-Dimorphic Liver Genes as Novel Biomarkers of Sex Transition

Roberta Tassinari iD, Alessia Tammaro, Gabriele Lori iD, Sabrina Tait iD, Andrea Martinelli, Luigia Cancemi, Paolo Frassanito, Francesca Maranghi iD

Cells · 01.02.2023 · 12 (3) · 474

DOI: 10.3390/cells12030474 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, online erschienen am 01.02.2023. Verfasst von Roberta Tassinari und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Gender Specific Medicine, Istituto Superiore di Sanità, 00144 Rome, Italy. Hauptthemen laut MEDLINE: Transgender Persons. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Transgender (TG) describes individuals whose gender identity differs from the social norms. TG people undergoing gender-affirming hormone therapy (HT) may be considered a sub-group of the population susceptible to environmental contaminants for their targets and modes of action. The aim of this study is to set appropriate HT doses and identify specific biomarkers to implement TG animal models. Four adult rats/group/sex were subcutaneously exposed to three doses of HT (plus control) selected starting from available data. The demasculinizing-feminizing models (dMF) were β-estradiol plus cyproterone acetate, at 0.09 + 0.33, 0.09 + 0.93 and 0.18 + 0.33 mg, respectively, five times/week. The defeminizing-masculinizing models (dFM) were testosterone (T) at 0.45, 0.95 and 2.05 mg, two times/week. Clitoral gain and sperm count, histopathological analysis of reproductive organs and liver, hormone serum levels and gene expression of sex-dimorphic CYP450 were evaluated. In the dMF model, the selected doses—leading to T serum levels at the range of the corresponding cisgender—induced strong general toxicity and cannot be used in long-term studies. In the dFM model, 0.45 mg of T represents the correct dose. In addition, the endpoints selected are considered suitable and reliable to implement the animal model. The sex-specific CYP expression is a suitable biomarker to set proper (de)masculinizing/(de)feminizing HT and to implement TG animal models.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Transgender PersonsMaleHumansFemaleRatsAnimalsGender IdentityRodentiaSemenTestosteroneLiverRisk AssessmentBiomarkers

Stichwörter der Autor:innen

cyproterone acetatecytochrome P450estrogenfeminizingmasculinizingsex-specific genestestosterone

Substanzen

TestosteroneBiomarkers

Autor:innen und Institutionen

  • Center for Gender Specific Medicine, Istituto Superiore di Sanità, 00144 Rome, Italy.
  • Experimental Animal Welfare Sector, Istituto Superiore di Sanità, 00144 Rome, Italy.

ORCID-Profile: Roberta Tassinari, Gabriele Lori, Sabrina Tait, Francesca Maranghi

Zitieren

APA

Tassinari, R., Tammaro, A., Lori, G., Tait, S., Martinelli, A., Cancemi, L., Frassanito, P., & Maranghi, F. (2023). Risk Assessment of Transgender People: Development of Rodent Models Mimicking Gender-Affirming Hormone Therapies and Identification of Sex-Dimorphic Liver Genes as Novel Biomarkers of Sex Transition. Cells, 12(3), 474. https://doi.org/10.3390/cells12030474

Vancouver

Tassinari R, Tammaro A, Lori G, Tait S, Martinelli A, Cancemi L, et al. Risk Assessment of Transgender People: Development of Rodent Models Mimicking Gender-Affirming Hormone Therapies and Identification of Sex-Dimorphic Liver Genes as Novel Biomarkers of Sex Transition. Cells. 2023;12(3):474. doi:10.3390/cells12030474

BibTeX
@article{Tassinari2023,
  author = {Tassinari, Roberta and Tammaro, Alessia and Lori, Gabriele and Tait, Sabrina and Martinelli, Andrea and Cancemi, Luigia and Frassanito, Paolo and Maranghi, Francesca},
  title = {Risk Assessment of Transgender People: Development of Rodent Models Mimicking Gender-Affirming Hormone Therapies and Identification of Sex-Dimorphic Liver Genes as Novel Biomarkers of Sex Transition},
  journal = {Cells},
  year = {2023},
  volume = {12},
  number = {3},
  pages = {474},
  doi = {10.3390/cells12030474}
}
Kostenlos starten →